AdvaMedDx Key Areas for Discussion on VALID Act DRAFT 5-29-2019
application/pdf
- 193.59 kB
Date:
09/06/2019 Disease Area:
Comments
AdvaMedDx Press Release on May 2019 Dx Reg Reform Stakeholder Letter to Hill
application/pdf
- 98 kB
Date:
09/06/2019 Disease Area:
AdvaMedDx Precertification Priorities 2-2019
application/pdf
- 102.98 kB
Date:
09/06/2019 Disease Area:
AdvaMedDx comments on VALID (redline) 2-15-2019
application/pdf
- 645.94 kB
Date:
09/06/2019 Disease Area:
AdvaMedDx comments on VALID (narrative) 2-15-2019
application/pdf
- 100.56 kB
Date:
09/06/2019 Disease Area:
AdvaMedDx VALID Act Comments Overview
application/pdf
- 100.79 kB
Date:
02/15/2019 Disease Area:
AdvaMedDx Comments on FDA Technical Assistance (TA) on Diagnostic Accuracy and Innovation Act (DAIA) House Discussion Draft
application/pdf
- 695.21 kB
Date:
08/27/2018 Disease Area:
AdvaMed Comments on Docket No. FDA-2018-D-0944; Draft Guidance for Industry; Investigational In Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination
application/pdf
- 788.49 kB
Date:
06/25/2018 Disease Area:
Comments to FDA on Select Updates for Recommendations for CLIA of 1988 Waiver Applications for Manufacturers of IVD Devices
application/pdf
- 965.08 kB
Date:
03/28/2018 Disease Area:
AdvaMedDx Comments on Preliminary Payment Rates Based on Private-Payer Data under PAMA 216
application/pdf
- 486.94 kB
Date:
10/24/2017 Disease Area: